Trimeris says sales of HIV drug Fuzeon declined from a year ago, with US sales down 28 percent

Trimeris says 1Q HIV drug sales fell 12 percent

DURHAM, N.C. — Trimeris Inc. said Wednesday that sales of its HIV drug Fuzeon fell 12 percent in the first quarter due to weaker demand in the U.S. and Canada.

Trimeris said Fuzeon sales dropped to $24.4 million from $27.8 million a year earlier. In the U.S. and Canada, revenue dropped 28 percent, to $7.2 million from $10 million. Total sales in other countries slipped 3 percent to $17.3 million from 417.8 million.

The overall result was slightly weaker than in the fourth quarter of 2009. During that period, Trimeris said Fuzeon sales totaled $25.5 million, including $9 million in the U.S. and $16.5 million in other countries. The drug is marketed by Trimeris’ partner Roche, which records all sales.

Trimeris plans to report its complete first-quarter results in early May.